Expression and diagnostic value of miR‑34c and miR‑141 in serum of patients with colon cancer

Wu,Huijing; Yan,Hongxia

doi:10.3892/ol.2020.11959

Expression and diagnostic value of miR‑34c and miR‑141 in serum of patients with colon cancer

Authors:
- Huijing Wu
- Hongxia Yan
View Affiliations

Affiliations: Department of Medical Oncology, Radio‑Chemotherapy Center, Hubei Cancer Hospital, Wuhan, Hubei 430079, P.R. China, Department of Oncological Radiotherapy, Hubei Cancer Hospital, Wuhan, Hubei 430079, P.R. China
Published online on: August 7, 2020 https://doi.org/10.3892/ol.2020.11959
Article Number: 98
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression of miR‑34c and miR‑141 in serum of colon cancer patients and their association with clinicopathological features and diagnostic value for colon cancer were investigated. A total of 64 patients with colon cancer admitted to Hubei Cancer Hospital from January 2016 to March 2018 were included in the experimental group, and 64 healthy subjects undergoing physical examination during the same period were the control group. The expression of miR‑34c and miR‑141 in serum of patients in the two groups were detected by RT‑qPCR, and the association of miR‑34c and miR‑141 with the clinicopathological characteristics of colon cancer patients was analyzed. The receiver operating characteristic (ROC) curve was used to assess the diagnostic efficiency of miR‑34c and miR‑141 in colon cancer. The expression of miR‑141 in serum of patients in the experimental group was significantly higher than that in the control group (P<0.05). Expression of miR‑34c in serum of patients in the experimental group was significantly lower than that in the control group (P<0.05) and the expression of miR‑34c and miR‑141 in serum of the experimental group were associated with tumor diameter, clinical stage, degree of differentiation and lymph node metastasis (P<0.05). AUC of serum miR‑34c in the diagnosis of colon cancer was 0.857 (95% CI: 0.795‑0.919), with the cut‑off value of 0.800, the diagnostic sensitivity of 84.38%, and the specificity of 68.75% and AUC of serum miR‑141 in the diagnosis of colon cancer was 0.876 (95% CI: 0.810‑0.941), with the cut‑off value of 0.282, the diagnostic sensitivity of 70.31%, and the specificity of 96.88%. The ROC curve for the diagnosis of colon cancer was further plotted in combination with serum miR‑34c and miR‑141. AUC of the two combined for the diagnosis of colon cancer was 0.929 (95% CI: 0.884‑0.974), with the cut‑off value of 0.566, the diagnostic sensitivity of 84.38%, and the specificity of 93.75%. In conclusion, miR‑34c and miR‑141 might be involved in the occurrence and progression of colon cancer and could be used as biological indicators for early diagnosis of colon cancer.

View Figures

View References

1	Nakagawa-Senda H, Hori M, Matsuda T and Ito H: Prognostic impact of tumor location in colon cancer: The Monitoring of Cancer Incidence in Japan (MCIJ) project. BMC Cancer. 19:4312019. View Article : Google Scholar : PubMed/NCBI
2	Zhu J, Dong H, Zhang Q and Zhang S: Combined assays for serum carcinoembryonic antigen and microRNA-17-3p offer improved diagnostic potential for stage I/II colon cancer. Mol Clin Oncol. 3:1315–1318. 2015. View Article : Google Scholar : PubMed/NCBI
3	Paudel MS, Mandal AK, Shrestha B, Poudyal NS, Kc S, Chaudhary S, Shrestha R and Goel K: Prevalence of organic colonic lesions by colonoscopy in patients fulfilling ROME IV criteria of irritable bowel syndrome. JNMA J Nepal Med Assoc. 56:487–492. 2018. View Article : Google Scholar : PubMed/NCBI
4	Mayanagi S, Kashiwabara K, Honda M, Oba K, Aoyama T, Kanda M, Maeda H, Hamada C, Sadahiro S, Sakamoto J, et al: Risk factors for peritoneal recurrence in stage II to III colon cancer. Dis Colon Rectum. 61:803–808. 2018. View Article : Google Scholar : PubMed/NCBI
5	Zhang Q, Zhang C, Ma JX, Ren H, Sun Y and Xu JZ: Circular RNA PIP5K1A promotes colon cancer development through inhibiting miR-1273a. World J Gastroenterol. 25:5300–5309. 2019. View Article : Google Scholar : PubMed/NCBI
6	Brase JC, Wuttig D, Kuner R and Sültmann H: Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer. 9:3062010. View Article : Google Scholar : PubMed/NCBI
7	Zeng M, Zhu L, Li L and Kang C: miR-378 suppresses the proliferation, migration and invasion of colon cancer cells by inhibiting SDAD1. Cell Mol Biol Lett. 22:122017. View Article : Google Scholar : PubMed/NCBI
8	Sheng S, Xie L, Wu Y, Ding M, Zhang T and Wang X: MiR-144 inhibits growth and metastasis in colon cancer by down-regulating SMAD4. Biosci Rep. 39:BSR201818952019. View Article : Google Scholar : PubMed/NCBI
9	Zhang W, Sun Z, Su L, Wang F, Jiang Y, Yu D, Zhang F, Sun Z and Liang W: miRNA-185 serves as a prognostic factor and suppresses migration and invasion through Wnt1 in colon cancer. Eur J Pharmacol. 825:75–84. 2018. View Article : Google Scholar : PubMed/NCBI
10	Chai B, Guo Y, Cui X, Liu J, Suo Y, Dou Z and Li N: MiR-223-3p promotes the proliferation, invasion and migration of colon cancer cells by negative regulating PRDM1. Am J Transl Res. 11:4516–4523. 2019.PubMed/NCBI
11	Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR and Zhang W: Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 6:e177452011. View Article : Google Scholar : PubMed/NCBI
12	Hagman Z, Haflidadottir BS, Ansari M, Persson M, Bjartell A, Edsjö A and Ceder Y: The tumour suppressor miR-34c targets MET in prostate cancer cells. Br J Cancer. 109:1271–1278. 2013. View Article : Google Scholar : PubMed/NCBI
13	Roy S, Levi E, Majumdar AP and Sarkar FH: Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol. 5:582012. View Article : Google Scholar : PubMed/NCBI
14	Liang Z, Li X, Liu S, Li C, Wang X and Xing J: MiR-141-3p inhibits cell proliferation, migration and invasion by targeting TRAF5 in colorectal cancer. Biochem Biophys Res Commun. 514:699–705. 2019. View Article : Google Scholar : PubMed/NCBI
15	Wan Y, Shen A, Qi F, Chu J, Cai Q, Sferra TJ, Peng J and Chen Y: Pien Tze Huang inhibits the proliferation of colorectal cancer cells by increasing the expression of miR-34c-5p. Exp Ther Med. 14:3901–3907. 2017. View Article : Google Scholar : PubMed/NCBI
16	Benson AB III, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, et al: Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 15:370–398. 2017. View Article : Google Scholar : PubMed/NCBI
17	Schweiger MR, Hussong M, Röhr C and Lehrach H: Genomics and epigenomics of colorectal cancer. Wiley Interdiscip Rev Syst Biol Med. 5:205–219. 2013. View Article : Google Scholar : PubMed/NCBI
18	Soler M, Estevez MC, Villar-Vazquez R, Casal JI and Lechuga LM: Label-free nanoplasmonic sensing of tumor-associate autoantibodies for early diagnosis of colorectal cancer. Anal Chim Act. 930:31–38. 2016. View Article : Google Scholar
19	Arnarson Ö, Butt-Tuna S and Syk I: Postoperative complication following colonic resection for cancer is associated with impaired long-term survival. Colorectal Dis. 21:805–815. 2019.PubMed/NCBI
20	Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR and Rabeneck L: Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 150:1–8. 2009. View Article : Google Scholar : PubMed/NCBI
21	Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H and Chejfec G: Use of colonoscopy to screen asymptomatic adults for colorectal cancer. N Engl J Med. 343:162–168. 2000. View Article : Google Scholar : PubMed/NCBI
22	Burt RW: Colon cancer screening. Gastroenterology. 119:837–853. 2000. View Article : Google Scholar : PubMed/NCBI
23	Ahmed FE, Ahmed NC, Gouda M and Vos P: MiRNAs for the diagnostic screening of early stages of colon cancer in stool or blood. Surg Case Rep Rev. 1:1–19. 2017. View Article : Google Scholar
24	Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM and Rosenberg A: MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol. 219:214–221. 2009. View Article : Google Scholar : PubMed/NCBI
25	Osaki M, Okada F and Ochiya T: miRNA therapy targeting cancer stem cells: A new paradigm for cancer treatment and prevention of tumor recurrence. Ther Deliv. 6:323–337. 2015. View Article : Google Scholar : PubMed/NCBI
26	Feng L, Ma H, Chang L, Zhou X, Wang N, Zhao L, Zuo J, Wang Y, Han J and Wang G: Role of microRNA-141 in colorectal cancer with lymph node metastasis. Exp Ther Med. 12:3405–3410. 2016. View Article : Google Scholar : PubMed/NCBI
27	Li F, Chen H, Huang Y, Zhang Q, Xue J, Liu Z and Zheng F: miR-34c plays a role of tumor suppressor in HEC-1-B cells by targeting E2F3 protein. Oncol Rep. 33:3069–3074. 2015. View Article : Google Scholar : PubMed/NCBI
28	Yang S, Li W, Sun H, Wu B, Ji F, Sun T, Chang H, Shen P, Wang Y and Zhou D: Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo. BMC Cancer. 15:9692015. View Article : Google Scholar : PubMed/NCBI
29	Gao Y, Feng B, Han S, Zhang K, Chen J, Li C, Wang R and Chen L: The roles of MicroRNA-141 in human cancers: From diagnosis to treatment. Cell Physiol Biochem. 38:427–448. 2016. View Article : Google Scholar : PubMed/NCBI
30	Tao F, Tian X, Lu M and Zhang Z: A novel lncRNA, Lnc-OC1, promotes ovarian cancer cell proliferation and migration by sponging miR-34a and miR-34c. J Genet Genomics. 45:137–145. 2018. View Article : Google Scholar : PubMed/NCBI
31	Wang J, Wang G, Li B, Qiu C and He M: miR-141-3p is a key negative regulator of the EGFR pathway in osteosarcoma. Onco Targets Ther. 11:44612018. View Article : Google Scholar : PubMed/NCBI